Jordi Río1, Alex Rovira2, Mar Tintoré3, Jaume Sastre-Garriga3, Joaquín Castilló3, Cristina Auger4, Carlos Nos3, Manuel Comabella3, Carmen Tur3, Ángela Vidal3, Xavier Montalbán3. 1. Centre d'esclerosi múltiple de Catalunya (CEM-Cat), Servei de Neurologia-Neuroimmunologia, Hospital Universitario Vall d'Hebron, Barcelona, Spain jrio@vhebron.net. 2. Unitat de Ressonància Magnètica (IDI), Servei de Radiologia, Hospital Universitario Vall d'Hebron, Barcelona, Spain. 3. Centre d'esclerosi múltiple de Catalunya (CEM-Cat), Servei de Neurologia-Neuroimmunologia, Hospital Universitario Vall d'Hebron, Barcelona, Spain. 4. Centre d'esclerosi múltiple de Catalunya (CEM-Cat), Servei de Neurologia-Neuroimmunologia, Hospital Universitario Vall d'Hebron, Barcelona, Spain Unitat de Ressonància Magnètica (IDI), Servei de Radiologia, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Abstract
BACKGROUND: In patients with relapsing-remitting multiple sclerosis (RRMS), a scoring system based on new magnetic resonance imaging (MRI) active lesions, relapses and sustained disability progression after a 1-year treatment with IFNβ predicted patient disability progression over time; however, this score had not been tested in patients receiving glatiramer acetate (GA). OBJECTIVE: The objective of this study was to evaluate whether this previous scoring system can also be applied to patients treated with GA. METHODS: This was a prospective, longitudinal study of 151 RRMS patients treated with GA. Their scores were constructed, based on the clinical and MRI activity after 1 year of therapy. Regression analysis was performed, in order to identify the response variables. RESULTS: The total possible score range was 0-3. Patients with a score of ≥ 2 and those with clinical activity (with or without MRI activity) during their first year of treatment were at increased risk of continuing with relapses and/or sustained disability in the next 2 years (odds ratio (OR): 38.8; p < 0.0001 and OR: 7.8; p < 0.009, respectively). CONCLUSIONS: In RRMS patients treated with GA, a combination of clinical activity measures may have prognostic value for identifying patients with disease activity in the next 2 years of therapy.
BACKGROUND: In patients with relapsing-remitting multiple sclerosis (RRMS), a scoring system based on new magnetic resonance imaging (MRI) active lesions, relapses and sustained disability progression after a 1-year treatment with IFNβ predicted patient disability progression over time; however, this score had not been tested in patients receiving glatiramer acetate (GA). OBJECTIVE: The objective of this study was to evaluate whether this previous scoring system can also be applied to patients treated with GA. METHODS: This was a prospective, longitudinal study of 151 RRMS patients treated with GA. Their scores were constructed, based on the clinical and MRI activity after 1 year of therapy. Regression analysis was performed, in order to identify the response variables. RESULTS: The total possible score range was 0-3. Patients with a score of ≥ 2 and those with clinical activity (with or without MRI activity) during their first year of treatment were at increased risk of continuing with relapses and/or sustained disability in the next 2 years (odds ratio (OR): 38.8; p < 0.0001 and OR: 7.8; p < 0.009, respectively). CONCLUSIONS: In RRMS patients treated with GA, a combination of clinical activity measures may have prognostic value for identifying patients with disease activity in the next 2 years of therapy.
Authors: Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman Journal: Nat Rev Neurol Date: 2015-09-15 Impact factor: 42.937
Authors: Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven Journal: Nat Rev Neurol Date: 2017-01-13 Impact factor: 42.937
Authors: Claudio Gasperini; Luca Prosperini; Mar Tintoré; Maria Pia Sormani; Massimo Filippi; Jordi Rio; Jacqueline Palace; Maria A Rocca; Olga Ciccarelli; Frederik Barkhof; Jaume Sastre-Garriga; Hugo Vrenken; Jette L Frederiksen; Tarek A Yousry; Christian Enzinger; Alex Rovira; Ludwig Kappos; Carlo Pozzilli; Xavier Montalban; Nicola De Stefano Journal: Neurology Date: 2018-12-26 Impact factor: 9.910
Authors: Peter Joseph Jongen; Ludovicus G Sinnige; Björn M van Geel; Freek Verheul; Wim I Verhagen; Ruud A van der Kruijk; Reinoud Haverkamp; Hans M Schrijver; J Coby Baart; Leo H Visser; Edo P Arnoldus; H Jacobus Gilhuis; Paul Pop; Monique Booy; Wim Lemmens; Rogier Donders; Anton Kool; Esther van Noort Journal: Patient Prefer Adherence Date: 2015-12-11 Impact factor: 2.711